Skip to main content

FAQs Increasingly Important In Health Reform Implementation


Grandfathered health plans under the Patient Protection and Affordable Care Act (ACA) can comply with the required disclosure requirement if they include the model disclosure language whenever a summary of the benefits under the plan is provided to participants and beneficiaries, according to the most recent questions and answers released by the Department of Labor’s Employee Benefit Security Administration.

This is the fourth in a series of frequently asked questions (FAQs) released by EBSA in order to “answer questions from stakeholders with a view to helping people understand the new law and benefit from it” (see Part I, Part II, Part III, and Part IV). EBSA and other agencies increasingly are turning to FAQs and other non-regulatory releases to provide guidance that helps employers and individuals comply with federal laws and regulations (see here, for example).

In “FAQs About the Affordable Care Act Implementation, Part IV,” this question is posed, “Must a grandfathered health plan provide the disclosure statement every time it sends out a communication, such as an EOB (explanation of benefits), to a participant or beneficiary?”

EBSA notes that “many plans distribute summary plan descriptions upon initial eligibility to receive benefits under the plan or coverage, during an open enrollment period, or upon other opportunities to enroll in, renew, or change coverage. While it is not necessary to include the disclosure statement with each plan or issuer communication to participants and beneficiaries (such as an explanation of benefits), the Departments encourage plan sponsors and issuers to identify other communications in which disclosure of grandfather status would be appropriate and consistent with the goal of providing participants and beneficiaries information necessary to understand and make informed choices regarding health coverage.”  In other words, ongoing communication may not be required but certainly is encouraged.

The EBSA release also confirms that certain plans that offer nonessential benefits under the ACA may impose lifetime limits in these plans. According to EBSA, the following type of plan, which imposes a per-child lifetime dollar limit on benefits provided under such plans, does not violate the lifetime limit prohibition:

  • operated before enactment of the Affordable Care Act ),

  • reimburses expenses for special treatment and therapy of eligible employees’ children with physical, mental, or developmental disabilities,

  • operated separately from the employer’s primary medical plans,

  • employees who are otherwise eligible may participate in the plan without participating in those primary medical plans.


More guidance in the form of FAQs can be expected on grandfathered plans, nonessential benefits, and other aspects of the ACA.

For a comprehensive analysis of the Patient Protection and Affordable Care Act, including the full text of the law and additional information on health reform and other developments in employee benefits, just click here.

Comments

Popular posts from this blog

clip on magnetic sunglasses visit here

Save with prescription glasses and sunglasses. Prescription eyeglasses with magnetic clip on sunglasses. A wide selection of colors and styles for every budget! -GlassesPoint. Prescription eyeglasses with magnetic clip on sunglasses. A wide selection of colors and styles for every budget! Free magnetic clip on with every pair of glasses.  The operator should contact lens Plano glasses a few days of Sun and Rx on the other person. Many people choose single vision lenses, designed for a specific use, such as prescription sunglasses. Clip-ons magnetic magnetic clip ons often come with their prescription glasses frames. Prescription glasses Goggles4u dollars from 29.99 with free shipping. Takumi neodium magnet glass features recipes that are light, strong and in. The combination of some normal prescription glasses and a pair of polarized glasses that glare-resistant to outdoor activities. clip on magnetic sunglasses visit here

The Tragedy of Underfunded Mental Health Care

Today’s Managing Health Care Costs Indicator is   19,900 The NY Times  on Friday had a deeply disturbing article on a murder that stunned the mental health community here in Massachusetts.    A long-term schizophrenic man, off his medicine and spiraling into incoherence, killed a young female counselor who was the sole worker at a group home in a Boston suburb.   His mother, who works at a Boston teaching hospital, was frantic with worry as her adult son, who had been arrested for assault multiple times, was becoming more psychotic.    It was hard for her to get anyone’s attention. The counselor was the first in her family to get a college degree, and had just decided to go to nursing school.    Now she’s dead – and her family had trouble scraping together the resources for a burial.   The schizophrenic will be imprisoned for the rest of his life – which ironically could be the best chance for him to get appropriate medical care. Both...

How a Well-Intended FDA Policy on Colchicine is Harming Patients

The road to hell is paved with good intentions. The FDA has reaffirmed the truth of this aphorism with its policy about Colchicine. Here's the story: I recently spoke with a friend who has a family member suffering from Familial Mediterranean Fever (FMF), an auto-inflammatory disorder, most commonly seen in eastern Mediterranean populations. The condition is characterized by recurrent painful inflammation of the abdomen, chest and joints, accompanied by fever. FMF is associated with mutation of a gene on chromosome 16 involved with regulating Pyrin, a protein that is part of the inflammatory response. There is no specific test for the disease. Diagnosis is made on the basis of symptoms, family history, and ruling out other conditions. Since the 1960s, Colchicine, a plant extract first used for treatment of gout two thousand years ago, has been used for treating FMF. As an ancient treatment widely used prior to formation of the FDA, Colchicine did not require FDA approval as a new ...